Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy.

Lung cancer (Amsterdam, Netherlands) - 1 Apr 2021

Wong Selina K, Alex Deepu, Bosdet Ian, Hughesman Curtis, Karsan Aly, Yip Stephen, Ho Cheryl

Abstract excerpt

OBJECTIVES: MET exon 14 skipping is a potentially targetable molecular alteration. The goals of this study were to identify patients treated in British Columbia with MET exon 14 skipping to understand prevalence, biology and response to treatment, and to identify molecular signatures that may predict for response or resistance to targeted MET therapy in the setting of advanced disease. MATERIALS AND METHODS: A...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Exons

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-met

Source

Identifiers

PMID: 33667719
DOI: 10.1016/j.lungcan.2021.02.030

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy.PMID 33667719Read ↗

MET Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations.Semantic proximity Read ↗

MET Exon 14 Skipping Mutations: Essential Considerations for Current Management of Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future ChallengesSemantic proximity Read ↗

Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations.Semantic proximity Read ↗

The Treatment of a New Entity in Advanced Non-small Cell Lung Cancer: MET Exon 14 Skipping Mutation.Semantic proximity Read ↗

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.Semantic proximity Read ↗

<i>MET</i> Exon 14 Skipping in Non-Small Cell Lung CancerSemantic proximity Read ↗

Non-small-cell lung cancer: how to manage MET exon 14 skipping mutant diseaseSemantic proximity Read ↗

MET exon 14 skipping mutations in non-small-cell lung cancer a 3 years screening experienceSemantic proximity Read ↗

Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 SkippingSemantic proximity Read ↗

MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutationsSemantic proximity Read ↗

Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.